Jiang et al. (2022) detected increased LOXL1 mRNA and protein expression in PAAD tissue. The LOX family, including LOXL1, might hold potential significance in PAAD oncogenesis and could serve as prognostic biomarkers, indicating a promising area for targeted therapy (Jiang et al., 2022). The gene discussed is LOX; the disease is pancreatic adenocarcinoma.